Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder

medRxiv(2024)10.1101/2024.04.02.24304677Source: DataRank Database

Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder is a research paper published in medRxiv (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)OA: greenTopics (39)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Siamak MahmoudianDehkordi ORCID,Matthew J. Sniatynski ORCID,Marina Belenky ORCID,Vasant R. Marur ORCID,A. John Rush ORCID

Live enrichment

PubMed:38633777 OpenAlex:https://openalex.org/W4393900135

National Institutes of Health

Grant: 5R01MH080880-03

Predictors of Treatment Response Relapse and Recurrence in Major Depression

National Institutes of Health

Grant: 5UL1RR025008-03

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH

National Institutes of Health

Grant: 5P50MH077083-03

Secondary Research Project: Monoamine Transporter Occupancy

National Institutes of Health

Grant: 5M01RR000039-33

GENERAL CLINICAL RESEARCH CENTER

National Institutes of Health

Grant: 5R01AG046171-03

Metabolic Networks and Pathways in Alzheimer's Disease

National Institutes of Health

Grant: 3U01AG061359-05S1

Characterizing the AD Metabolome in Brain Tissue Samples of Individuals from Diverse Populations

National Institutes of Health

Grant: 5R01MH108348-04

Metabolomic Signatures Predictive of Outcomes to Treatments for Major Depression

NIA NIH HHS

Grant: R01 AG046171

NIMH NIH HHS

Grant: R01 MH108348

NCRR NIH HHS

Grant: M01 RR000039

NIMH NIH HHS

Grant: R01 MH080880

NCATS NIH HHS

Grant: UL1 TR002378

NIA NIH HHS

Grant: U01 AG061359

NIMH NIH HHS

Grant: P50 MH077083

NCRR NIH HHS

Grant: UL1 RR025008

greenLicense: cc-by-nc-nd

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2024/04/03/2024.04.02.24304677.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2024.04.02.24304677

repositoryhttp://dx.doi.org/10.1101/2024.04.02.24304677

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38633777

Fields of Study

Tryptophan and brain disordersTreatment of Major DepressionMental Health Research Topics03 medical and health sciences0302 clinical medicine

Keywords

EscitalopramDuloxetineReuptake inhibitorMajor depressive disorderAntidepressantPharmacologySerotonin reuptake inhibitorSerotoninTryptophan hydroxylaseHamilton Rating Scale for DepressionDuloxetine HydrochlorideReuptakePsychologyInternal medicineMedicinePsychiatryAnxietySerotonergicCognitionAdultMaleNeurotransmitter AgentsIndolesCognitive Behavioral TherapyTryptophanMiddle AgedArticleHumansMetabolomicsTyrosineFemaleSerotonin and Noradrenaline Reuptake InhibitorsSelective Serotonin Reuptake InhibitorsSignal Transduction

Sustainable Development Goals

SDG 0: Good health and well-being